Skip Navigation

Rheumatology 2008 47(2):212-218; doi:10.1093/rheumatology/kem351
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dinser, R.
Right arrow Articles by Sester, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dinser, R.
Right arrow Articles by Sester, M.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-{alpha} blocking drugs using a novel flow-cytometric interferon-{gamma} release assay

R. Dinser1, M. Fousse2, U. Sester2, K. Albrecht1, M. Singh3, H. Köhler2, U. Müller-Ladner1 and M. Sester2

1Department of Internal Medicine and Rheumatology, Justus-Liebig University of Giessen, Kerckhoff Clinic, Bad Nauheim, 2Department of Internal Medicine IV, University Hospital of the Saarland, Homburg and 3Helmholtz Center for Infection Research and Lionex GmbH, Braunschweig, Germany.

Correspondence to: R. Dinser, Department of Internal Medicine and Rheumatology, Justus-Liebig University of Giessen, Kerckhoff Clinic, Benekestrasse 2-8, D-61231 Bad Nauheim, Germany. E-mail: r.dinser{at}kerckhoff-klinik.de


   Abstract

Objective. To compare the efficacy of the conventional skin test and a novel flow cytometric whole blood assay in the diagnosis of latent tuberculosis infection (LTBI) in patients with rheumatological diseases evaluated for treatment with TNF-{alpha}-blocking agents.

Methods. Prospective study of 97 consecutively enrolled patients, who were assessed for the presence of LTBI through clinical history, Mendel–Mantoux skin testing and chest X-ray. In addition, T-cell reactivity towards tuberculin (PPD, purified protein derivative) and the Mycobacterium tuberculosis-specific proteins ESAT-6 and CFP-10 was determined ex vivo using a flow cytometric whole blood assay.

Results. After standard screening, 15% of patients receiving TNF-{alpha}-blocking therapy were pretreated with isoniazide (INH), another 5% of patients did not receive TNF-{alpha}-blocking therapy because of LTBI. PPD-reactivity in the skin was observed in 14% of patients compared with 39% with the whole blood test. Analysis of the M. tuberculosis-specific response to ESAT-6 and CFP-10 revealed positive results in 16% of patients. Using a decision tree incorporating history, chest X-ray and either skin-test or ESAT-6/CFP-10 results, 18 or 22% of the patients, respectively, were classified as latently infected with M. tuberculosis. Four patients treated with INH because of a positive skin reaction did not show reactivity to ESAT-6/CFP-10 in the whole blood assays. Another six patients not pretreated with INH because of negative skin tests would have received INH, had the results of the whole blood assay been taken into account.

Conclusion. The Mendel–Mantoux skin test has a low sensitivity and specificity for the diagnosis of LTBI in this cohort of patients, potentially resulting in both over- and under-treatment with prophylactic INH when compared with the flow cytometric analysis of whole blood T-cell reactivity to proteins specific to M. tuberculosis. Use of T-cell based in vitro tests may help to refine diagnostic testing for LTBI.

KEY WORDS: Latent tuberculosis, Tuberculin, TNF-{alpha}-blocking drugs

Submitted 30 April 2007; revised version accepted 30 November 2007.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
The Journal of RheumatologyHome page
N. INANC, S. Z. AYDIN, S. KARAKURT, P. ATAGUNDUZ, S. YAVUZ, and H. DIRESKENELI
Agreement Between Quantiferon-TB Gold Test and Tuberculin Skin Test in the Identification of Latent Tuberculosis Infection in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
J Rheumatol, December 1, 2009; 36(12): 2675 - 2681.
[Abstract] [Full Text] [PDF]


Home page
The Journal of RheumatologyHome page
B. SOBORG, M. RUHWALD, M. L. HETLAND, S. JACOBSEN, A. B. ANDERSEN, N. MILMAN, V. O. THOMSEN, D. V. JENSEN, A. KOCH, J. WOHLFAHRT, et al.
Comparison of Screening Procedures for Mycobacterium tuberculosis Infection Among Patients with Inflammatory Diseases
J Rheumatol, September 1, 2009; 36(9): 1876 - 1884.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
F. Bartalesi, S. Vicidomini, D. Goletti, C. Fiorelli, G. Fiori, D. Melchiorre, E. Tortoli, A. Mantella, M. Benucci, E. Girardi, et al.
QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases
Eur. Respir. J., March 1, 2009; 33(3): 586 - 593.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.